Table 1.
Study population and treatments features by pre-exposition to neo/adjuvant anti HER2 treatments among patients with recurrent MBC.
| Factor | Pre-exposition status | Total | Chi-square test, P-value | ||
|---|---|---|---|---|---|
| Class | Relapsed not pre-exposed to trastuzumab N = 1070 |
Relapsed and pre-exposed to trastuzumab N = 1343 |
|||
| Period of MBC diagnosis | 2008-2012 | 651 | 687 | 1338 | <.001 |
| 60.8% | 51.2% | 55.4% | |||
| 2012-2018 | 419 | 656 | 1075 | ||
| 39.2% | 48.8% | 44.6% | |||
| Age at MBC | 18-49 | 207 | 520 | 727 | <.001 |
| 19.3% | 38.7% | 30.1% | |||
| 50-69 | 525 | 651 | 1176 | ||
| 49.1% | 48.5% | 48.7% | |||
| 70 and + | 338 | 172 | 510 | ||
| 31.6% | 12.8% | 21.2% | |||
| Performance Status at MBC diagnosis | 0 | 236 | 295 | 531 | .47 |
| 22.1% | 22% | 22% | |||
| 1 | 224 | 269 | 493 | ||
| 20.9% | 20% | 20.4% | |||
| 2 | 73 | 78 | 151 | ||
| 6.8% | 5.8% | 6.3% | |||
| 3-4 | 42 | 41 | 83 | ||
| 3.9% | 3.1% | 3.4% | |||
| PS NA | 495 | 660 | 1155 | ||
| 46.3% | 49.1% | 47.9% | |||
| Histological type | Invasive Ductal Carcinoma (IDC) | 770 | 1146 | 1916 | <.001 |
| 72.9% | 85.5% | 79.9% | |||
| Invasive Lobular Carcinoma (ILC) | 84 | 61 | 145 | ||
| 7.9% | 4.6% | 6,1% | |||
| IDC and ILC | 22 | 12 | 34 | ||
| 2.1% | 0.9% | 1.4% | |||
| Other | 181 | 121 | 302 | ||
| 17.1% | 9% | 12.6% | |||
| Hormone receptors status | HR− | 245 | 501 | 746 | <.001 |
| 22.9% | 37.3% | 30.9% | |||
| HR+ | 825 | 842 | 1667 | ||
| 77.1% | 62.7% | 69.1% | |||
| Number of metastatic sites | 1 | 567 | 772 | 1339 | .15 |
| 53% | 57.4% | 55.6% | |||
| 2 | 271 | 299 | 570 | ||
| 25.3% | 22.3% | 23.6% | |||
| 3 | 140 | 158 | 298 | ||
| 13.1% | 11.8% | 12.3% | |||
| 4 and more | 92 | 114 | 206 | ||
| 8.6% | 8.5% | 8.5% | |||
| Type of metastases | Visceral metastasis | 577 | 617 | 1194 | <.001 |
| 53.9% | 45.9% | 49.5% | |||
| Bone only metastatis | 178 | 188 | 366 | ||
| 16.6% | 14% | 15.2% | |||
| Brain metastasis | 71 | 284 | 355 | ||
| 6.6% | 21.1% | 14.7% | |||
| Other | 244 | 254 | 498 | ||
| 22.9% | 19% | 20.6% | |||
| Disease-free interval* (months) | 6-24 | 133 | 400 | 533 | <.001 |
| 12.4% | 29.8% | 22.1% | |||
| 24-36 | 95 | 316 | 411 | ||
| 8.9% | 23.5% | 17% | |||
| 36-48 | 87 | 210 | 297 | ||
| 8.1% | 15.6% | 12.3% | |||
| >48 | 755 | 417 | 1172 | ||
| 70.6% | 31.1% | 48.6% | |||
| Systemic treatment received in early setting | |||||
| Anthracyclines | No | 574 | 253 | 827 | <.001 |
| 53.6% | 18.8% | 34.3% | |||
| Yes | 496 | 1090 | 1586 | ||
| 46.4% | 81.2% | 65.7% | |||
| Taxanes | No | 815 | 110 | 925 | <.001 |
| 76.2% | 8.2% | 38.3% | |||
| Yes | 255 | 1233 | 1488 | ||
| 23.8% | 91.8% | 61.7% | |||
| Other anti-HER2 | No | 1065 | 1299 | 2364 | <.001 |
| 99.5% | 96.7% | 98% | |||
| Yes | 5 | 44 | 49 | ||
| 0.5% | 3.3% | 2% | |||
| Systemic treatment in 1st line metastatic setting | |||||
| Type of systemic treatment* | HER2-double blockade + taxane | 157 | 261 | 418 | <.001 |
| 17.9% | 22.1% | 20.3% | |||
| HER2-double blockade + other | 27 | 48 | 75 | ||
| 3.1% | 4.1% | 3.6% | |||
| TDM1 | 16 | 72 | 88 | ||
| 1.8% | 6.1% | 4.3% | |||
| At least 1 anti-HER2 | 505 | 674 | 1179 | ||
| 57.7% | 57% | 57.3% | |||
| No anti-HER2 | 170 | 127 | 297 | ||
| 19.4% | 10.7% | 14.4% | |||
| NA | 195 | 161 | 356 | ||
*From diagnosis of the primary tumor.
Abbreviation: HR: hormone receptor status.